Diagnostic Reimbursement: Does It Pay For Insurers To Think Long Term?
This article was originally published in The Gray Sheet
Executive Summary
Consolidation among healthcare insurers could be a boon for diagnostic firms that are able to demonstrate the long-term medical and cost benefits of their test
You may also be interested in...
Cost Effectiveness Of DTC Ads Varies In Securing Cancer Test Reimbursement
Exact Sciences expects cost-effectiveness studies for the PreGen-Plus genomics-based colorectal cancer screening test to support relatively high reimbursement for the device
Cost Effectiveness Of DTC Ads Varies In Securing Cancer Test Reimbursement
Exact Sciences expects cost-effectiveness studies for the PreGen-Plus genomics-based colorectal cancer screening test to support relatively high reimbursement for the device
Exact Data On PreGen Plus Colorectal Cancer Genomics Test Due In 2003
Exact Sciences will commercially release itsPreGen-Plus genomics-based colorectal cancer screening test technology after partnering with a large clinical reference laboratory, the firm says. A deal is expected by year-end